La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !
Teva Pharmaceutical Industries Gestione
Gestione criteri di controllo 2/4
Teva Pharmaceutical Industries' Il CEO è Richard Francis, nominato in Jan2023, e ha un mandato di 1.58 anni. la retribuzione annua totale è $ 25.71M, composta da 6.2% di stipendio e 93.8% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.011% delle azioni della società, per un valore di $ 2.25M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 2.4 anni e 7.1 anni.
Informazioni chiave
Richard Francis
Amministratore delegato
US$25.7m
Compenso totale
| Percentuale dello stipendio del CEO | 6.2% |
| Mandato del CEO | 1.6yrs |
| Proprietà del CEO | 0.01% |
| Durata media del management | 2.4yrs |
| Durata media del Consiglio di amministrazione | 7.1yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Teva's Transformation: From Generics Leader To Branded Drug Innovator
Aug 14Teva Pharmaceutical Industries Limited (NYSE:TEVA) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year
Aug 02
Teva's Q2 Outlook: Key Developments In Biosimilars And Pipeline Drugs
Jul 26Is Teva Pharmaceutical Industries (NYSE:TEVA) A Risky Investment?
Jul 12Teva Pharmaceutical: Buy This Bargain Before It's Gone
Jun 07Teva Pharmaceutical Industries Limited (NYSE:TEVA) Stock Catapults 27% Though Its Price And Business Still Lag The Industry
May 14Teva: Sustained Revenue Growth Amid Financial Strain (Rating Downgrade)
May 09Teva Pharmaceutical Industries (NYSE:TEVA) Has A Somewhat Strained Balance Sheet
Mar 26Teva Pharmaceutical Industries: Potential Outweighs Concerns
Mar 25Teva And Alvotech: Simlandi Approval Opens New Generic Market Opportunities
Feb 26A Review Of Teva's Prospects
Feb 15Teva Pharmaceutical Industries Limited's (NYSE:TEVA) Business And Shares Still Trailing The Industry
Jan 07These 4 Measures Indicate That Teva Pharmaceutical Industries (NYSE:TEVA) Is Using Debt In A Risky Way
Dec 11Teva: 4 Key Drivers For A 2024 Revival (Upgraded Rating)
Dec 08Teva: Deeply Undervalued FCF Machine
Nov 20Teva: Focus On Innovation And Growth Means The Times They Are A Changing
Sep 14Teva Pharmaceutical Industries (NYSE:TEVA) Has No Shortage Of Debt
Sep 09The Mighty Teva Pharmaceutical: Unveiling A Bullish Scenario You Must Consider
Aug 26Teva Q2 Earnings: Austedo And Anda Growth Impress, But Challenges Remain
Aug 02Teva Pharmaceutical: Lacking Capabilities For Strategic Investments
Jul 20Teva Pharmaceutical: New Growth Plan Could Restore Investor Confidence
Jun 15Here's Why Teva Pharmaceutical Industries (NYSE:TEVA) Is Weighed Down By Its Debt Load
Jun 06Is Teva Pharmaceutical Industries (NYSE:TEVA) A Risky Investment?
Feb 20What To Expect From Teva Pharmaceutical In 2023 With A New CEO
Feb 15Can Teva Pharmaceutical's Q4 results bring positive surprise?
Feb 07Teva Pharmaceutical: Stuck In A Cycle Of Hope And Disappointment
Jan 19Tamiflu supplies released from national stockpile as nationwide shortage persists
Jan 12Teva Pharmaceutical: 2023 Could Finally Be The Stock's Breakout Year
Dec 28Federal appeals court temporarily blocks generics of Vanda's Hetlioz by Teva, Apotex
Dec 16Boston jury orders Lilly to pay $176.5M to Teva in migraine drug patent suit
Nov 10Teva Pharmaceutical to pay New York $523M as part of opioid settlement
Nov 03Teva data indicates long-term benefit of Austedo for chorea associated with Huntington's
Oct 18Novartis division Sandoz reports supply issue of generic ADHD drug Adderall - Bloomberg
Oct 06Teva Pharmaceutical: Slow And Steady Road To A Higher Share Price
Sep 28Teva Pharmaceutical: Past Behind And A Promising 2023
Sep 16Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Guadagni aziendali |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$453m |
| Mar 31 2024 | n/a | n/a | -US$478m |
| Dec 31 2023 | US$26m | US$2m | -US$559m |
Compensazione vs Mercato: La retribuzione totale di Richard ($USD 25.71M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 13.21M ).
Compensazione vs guadagni: Dati insufficienti per confrontare la retribuzione di Richard con le performance aziendali.
AMMINISTRATORE DELEGATO
Richard Francis (56 yo)
1.6yrs
Mandato
US$25,706,880
Compensazione
Mr. Richard D. Francis serves as President and Chief Executive Officer at Teva Pharmaceutical Industries Limited since January 01, 2022 and serves as its Director. Mr. Francis served as Division Head and C...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| President | 1.6yrs | US$25.71m | 0.011% $ 2.3m | |
| Executive VP & CFO | 4.7yrs | US$4.94m | 0.064% $ 13.3m | |
| Executive Vice President of International Markets Commercial | 3yrs | US$3.73m | 0.028% $ 5.8m | |
| Executive Vice President of European Commercial | 6.8yrs | US$5.16m | 0% $ 0 | |
| Executive Vice President of Global Operations | less than a year | Nessun dato | Nessun dato | |
| Senior VP & Chief Accounting Officer | 2.8yrs | Nessun dato | 0.00046% $ 95.8k | |
| Head of Investor Relations | no data | Nessun dato | Nessun dato | |
| Senior Vice President | 2.1yrs | Nessun dato | Nessun dato | |
| Executive VP & Chief Legal Officer | less than a year | Nessun dato | Nessun dato | |
| Acting Head of Global Human Resources | less than a year | Nessun dato | 0% $ 0 | |
| Senior Vice President of Investor Relations | no data | Nessun dato | Nessun dato | |
| Senior VP & Chief Internal Auditor | 10.3yrs | Nessun dato | Nessun dato |
2.4yrs
Durata media
52.5yo
Età media
Gestione esperta: Il team dirigenziale di TEVA è considerato esperto (durata media dell'incarico 2.4 anni).
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| President | no data | US$25.71m | 0.011% $ 2.3m | |
| Independent Chairman of the Board | 9.6yrs | US$539.99k | 0.036% $ 7.5m | |
| Independent Director | 15.6yrs | US$340.00k | 0.18% $ 38.5m | |
| Independent Director | 8.9yrs | US$355.00k | 0.0094% $ 2.0m | |
| Independent Director | 7.1yrs | US$340.00k | 0.0084% $ 1.8m | |
| Independent Director | 8.9yrs | US$330.00k | 0.0092% $ 1.9m | |
| Independent Director | 4.2yrs | US$325.46k | 0.0056% $ 1.2m | |
| Independent Director | 2.8yrs | US$330.00k | 0.0043% $ 904.3k | |
| Independent Director | 7.1yrs | US$327.87k | 0.0084% $ 1.8m | |
| Independent Director | 6.2yrs | US$315.25k | 0.0078% $ 1.6m | |
| Independent Director | less than a year | US$176.66k | Nessun dato |
7.1yrs
Durata media
64yo
Età media
Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di TEVA sono considerati esperti (durata media dell'incarico 7.1 anni).